Developing a Canadian managed entry approach for new innovation: What can Canada learn from Europe?

Many new therapies coming to the market are not well served by the traditional drug reimbursement approaches currently employed by Canada’s public plans. A growing number of European regulatory authorities have been using novel managed entry agreements (MEA) and innovative access agreements (IAA) to accelerate approval times and improve availability to patients.


Discover. Learn.

Informative content to keep you up to date on the most pressing issues facing our industry.